On another note, if thrice weekly does pick up steam and garners any sort of significant market share, what would stop MNTA or MYL from submitting an ANDA for thrice weekly as well (assuming approval of their generic copax of course)?
I don't know much about the thrice weekly patents, but I can't see them being especially strong (could be totally off-base here)...
News 
Market Data 
Discover 
